Targeting pathological
crosslinking ​to reverse fibrosis and extend health-span

Isterian’s inhibitors target transglutaminase 2 (TG2), a key crosslinking enzyme

TG2 crosslinked proteins are highly resistant to degradation, which leads to their build-up in aged fibrotic tissues, as observed in diseases like idiopathic pulmonary fibrosis (IPF)